When a wound shows signs of infection or elevated microbial burden, the choice of topical antimicrobial agent matters more than most clinicians realize. Three agents dominate the conversation: PHMB (polyhexamethylene biguanide), iodine-based products, and silver-based dressings and gels. Each has a distinct mechanism of action, a different cytotoxicity profile, and a different clinical sweet spot.

This post breaks down how each agent works, where the evidence supports its use, and how to think about selecting the right one for the wound in front of you.

A Quick Overview of Each Agent

PHMB (Polyhexamethylene Biguanide)

PHMB is a synthetic cationic polymer that disrupts bacterial cell membranes through a physical mechanism — it binds to the negatively charged membrane, destabilizes it, and causes cell death through leakage of intracellular contents. Because the mechanism is physical rather than metabolic, resistance development is extremely rare. PHMB is the active ingredient in Omnicide® Antimicrobial Gel and a growing number of wound irrigation solutions and dressings.

Iodine (Povidone-Iodine and Cadexomer Iodine)

Iodine has been used as a wound antiseptic for over a century. It works by releasing free iodine, which oxidizes bacterial proteins and disrupts cellular function. Two forms are relevant in modern wound care: povidone-iodine (PVP-I), a solution or gel used for wound cleansing and irrigation, and cadexomer iodine, a slow-release formulation embedded in a dressing matrix that delivers iodine gradually as it absorbs exudate.

Silver

Silver exerts its antimicrobial effect through silver ions (Ag⁺), which bind to bacterial proteins and DNA, disrupting multiple cellular processes simultaneously. Silver is delivered in wound care through a wide range of dressing formats — nanocrystalline silver, silver sulfadiazine, silver-impregnated foams and alginates — each with different release kinetics and clinical applications.

Head-to-Head Comparison

Cytotoxicity: The Factor Most Clinicians Underweight

Antimicrobial efficacy is only half the equation. An agent that kills bacteria but also damages fibroblasts, keratinocytes, and granulation tissue can slow healing — sometimes significantly. This is the central critique of traditional povidone-iodine solutions in chronic wound management.

Multiple in vitro studies have demonstrated that PVP-I at standard concentrations is cytotoxic to the cells responsible for wound repair. The clinical implication: using PVP-I repeatedly on a chronic wound may reduce bacterial load while simultaneously impairing the tissue's ability to close. Cadexomer iodine, which releases iodine slowly and at lower concentrations, has a more favorable profile and is better supported for chronic wound use.

PHMB consistently demonstrates low cytotoxicity at therapeutic concentrations in peer-reviewed literature. Silver falls in between — most modern silver dressings are formulated to minimize cytotoxic effects, but the evidence varies by product and formulation.

Biofilm: Where the Differences Matter Most

Biofilm is present in an estimated 60–80% of chronic wounds and is a primary driver of wound stagnation. It is significantly more resistant to antimicrobial agents than planktonic (free-floating) bacteria — often requiring concentrations 100–1,000 times higher to achieve the same kill rate.

PHMB has demonstrated strong biofilm penetration and disruption in multiple studies, making it one of the more effective topical agents for biofilm-heavy wounds. Silver also shows meaningful biofilm activity, particularly in nanocrystalline formulations. Standard PVP-I has more limited biofilm penetration, though cadexomer iodine performs better due to its sustained-release mechanism.

For wounds where biofilm is a confirmed or suspected barrier to healing, PHMB-based products like Omnicide® and silver-based dressings are generally the stronger clinical choices.

When to Use Each Agent

Choose PHMB when:

• The wound has a significant biofilm burden or has stalled despite standard care
• Tissue preservation is a priority — diabetic foot ulcers, pressure injuries, wounds near tendons or bone
• Long-term antimicrobial management is needed without resistance risk
• You want a gel formulation that maintains wound contact and moisture balance
• The patient has a history of sensitivity to iodine or silver

Choose cadexomer iodine when:

• The wound has heavy exudate and you want a dressing that absorbs while delivering antimicrobial activity
• Slough debridement is also a goal — cadexomer iodine has mild autolytic debridement properties
• Venous leg ulcers with moderate-to-heavy bacterial burden
• Short-to-medium term antimicrobial management (not indefinite use)

Choose silver when:

• The wound has a broad bacterial burden and you want a dressing-integrated solution
• Post-surgical wounds or burns where infection prevention is the primary goal
• The wound type matches a specific silver dressing format (foam, alginate, contact layer)
• You need sustained antimicrobial activity over multiple days between dressing changes

Avoid standard PVP-I solutions for chronic wounds:

• Repeated application on granulating tissue — cytotoxicity risk outweighs antimicrobial benefit
• Wounds where healing has stalled — PVP-I may be contributing to the problem
• Patients with thyroid conditions — systemic iodine absorption is a documented concern with large wounds

Can You Use More Than One?

In practice, combination approaches are common — particularly PHMB gel applied to the wound bed with a silver-containing secondary dressing. The two agents work through different mechanisms and are generally compatible. What clinicians should avoid is layering multiple iodine-based products or using PVP-I alongside agents that may be inactivated by organic matter.

As always, the goal is a protocol that reduces microbial burden without impeding the healing cascade. The best antimicrobial agent is the one that addresses the specific barrier in the specific wound — not the one that's been in the supply closet the longest.